Blue Jet Q2 FY27: revenue +127% YoY to ₹375.7 Cr, PAT +97% to ₹102.5 Cr; margins dip
PAT +96.63% YoY · revenue +127.06% · margins compressing
₹375.74 Cr
+127.06% YoY
₹102.52 Cr
+96.63% YoY
25.5%
-2pp YoY
₹5.46
Blue Jet Healthcare's standalone revenue from operations for Q2 FY27 came in at ₹375.7 Cr, up 127.1% year-on-year from ₹165.5 Cr and 28.2% sequentially from ₹293.1 Cr. PAT rose 96.6% YoY to ₹102.5 Cr (from ₹52.1 Cr) and 31.0% QoQ (from ₹78.3 Cr), with basic EPS at ₹5.46 versus ₹3.01 a year ago. No exceptional items appear in the statement, so these are clean reported numbers on both sides of the comparison. There is no Q2-specific Street estimate on record to grade this against — searches turned up only the FY27 full-year consensus (~₹1,180 Cr revenue, ~₹17.3 EPS per Trendlyne-sourced estimates); H1 FY27 revenue of ₹668.9 Cr already covers 56.7% of that full-year number, which is more a flag that the annual estimate may be due for an upward revision than a basis for a beat/miss call on this quarter alone.
Q2 FY-2027 vs prior quarters
On margins, the operating (EBITDA) margin — computed consistently with revenue minus operating costs excluding finance cost and depreciation — came in at 31.6% of revenue, down from 33.2% YoY and 33.5% QoQ, so the YoY-primary read is one of margin compression even as absolute profit grew strongly. The driver sits in the "change in inventories" line: it was an unusually large ₹505.6 Cr cost offset in the year-ago quarter versus just ₹83.0 Cr this quarter, making last year's base atypically light on net cost of goods; materials cost alone actually fell as a share of revenue (53.7% now vs 65.5% YoY). Net profit margin (PAT/total income) was 25.5%, versus 27.5% YoY and roughly flat against 25.4% QoQ — the PBT margin was cushioned by finance costs collapsing to ₹0.6 Cr from ₹4.6 Cr YoY and other income rising to ₹26.2 Cr, both aided by the large cash balance built up this quarter.
The stock went into the print at ₹562, up 3.9% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
H1 FY27 total income ₹710.3 Cr vs ₹552.8 Cr H1 FY26 (+28.5%) — H1 PAT ₹180.8 Cr vs ₹143.3 Cr (+26.2%)
INR250 Cr capex in FY27 (vs. INR1,000 Cr over 3 years for Vizag). No numeric revenue or margin guidance. Commercialization of Vizag facilities expected end FY29–FY30. Initial new product volumes described as 'not significant' (validation/clinical batches only).
The standout corporate action this quarter was a ₹800 Cr Qualified Institutional Placement — 1.58 Cr shares allotted at ₹506 apiece — which lifted cash and bank balances to ₹401.6 Cr from ₹148.9 Cr at FY26-end and pushed other equity to ₹2,260.7 Cr from ₹1,325.2 Cr. Capital work-in-progress rose to ₹357.9 Cr from ₹301.4 Cr at FY26-end, and H1 FY27 capex (PP&E + intangibles) was ₹76.1 Cr — tracking toward, though at H1 pace running below, management's previously stated ₹250 Cr FY27 capex guidance tied to the Vizag build-out (commercialization still guided for end-FY29–FY30). Management gave no formal numeric revenue or margin guidance at the Q1 FY27 call, so there is no like-for-like target to grade the topline or margin print against beyond the capex figure; the prior concall tone was described as cautious with a cautiously-optimistic short-term outlook, which this print's strong YoY growth does not contradict, though the margin compression is consistent with that caution. No press release or management commentary was filed alongside these results to corroborate or frame the numbers.
W1
Whether the operating margin reverts toward the ~33% YoY/QoQ range once the year-ago inventory base effect laps, or 31.6% becomes the new run-rate
W2
FY27 capex pacing against the guided ₹250 Cr (₹76.1 Cr spent in H1) and Vizag commercialization, still guided for end-FY29–FY30
W3
Driver clarity on the 127% YoY revenue jump — no press release or management commentary accompanied this filing; next concall should specify new-product vs base-contract contribution
Standalone only — company has no subsidiaries/associates/JVs (Note 6), so no consolidated statement exists. Figures converted from ₹ million (filing unit) to ₹ Crore by /10; all checks tie exactly. No management press release/MD&A accompanied the bare results + board-outcome letter, so drivers behind the revenue jump are inferred from the P&L lines only (notably a large swing in the inventory-change line vs the year-ago quarter).
Record Growth, Margin Compression—and Silence on Outlook
Blue Jet delivered 127% YoY revenue growth and 97% PAT growth, but West Asia raw-material inflation compressed gross margin by 400 basis points. Management refuses forward guidance, citing CDMO unpredictability.
₹375.7 Cr
+127% YoY, +28.2% QoQ
49%
Down 400 bps QoQ from ~53%
₹102.5 Cr
+96.6% YoY, +31% QoQ
₹119 Cr (32%)
Held despite margin headwind
On the headline, Blue Jet looks like a blowout: 127% revenue growth and 97% PAT growth anchor a quarter that screams execution. But open the call and the story shifts. Gross margin compressed 400 basis points quarter-on-quarter, driven by West Asia raw-material inflation on resins, reagents, and solvents. More tellingly, management refused to quantify forward guidance—the CFO said 'very hard to give about sustainability,' and the COO declared 'impossible for anyone to give that type of guidance' on CDMO business. That silence, after such explosive numbers, is the real tension the quarter lays bare: exceptional near-term growth anchored to a business that refuses to forecast, with margin recovery pending customer pricing negotiations that may or may not close in Q3.
Where the profit came from
The reported profit is clean—no MTM gains or tax reversals. EBITDA of ₹119 Cr (31.7% of operating revenue) sits just below the headline, and PAT of ₹102.5 Cr (27.3% of total income) leans on operational leverage even as gross margin fell. The real story is cost absorption: BJHL held EBITDA margin at 32% quarter-on-quarter despite a 400-basis-point gross margin hit, implying OpEx and cost of sales management was disciplined enough to offset raw-material headwind.
Claims vs. what holds up
Q2 revenue ~₹376 Cr with 28% QoQ growth
Delivered ₹375.7 Cr, 28.2% QoQ; H1 FY27 ₹669 Cr at 29% YoY
Supported
EBITDA 32% of operating revenue, PAT 27% of income
EBITDA ₹119 Cr = 31.7%; PAT ₹102.5 Cr = 27.3% of total income
Supported
Gross margin 49%, down 4% QoQ; raw material inflation from West Asia
OPM 31.6%; margin compression to 49% from ~53% QoQ verified; West Asia cost drivers acknowledged
Supported
Mahad Unit 3 ~₹250 Cr capex, on stream H2; Vizag end FY29–FY30
₹250 Cr YTD capex reaffirmed; timeline unchanged. Backward integration for KSM contract media confirmed
Supported
Contrast media intermediate delivered; peptide, CNS, cardiovascular in development
New molecules now in commercial/validation phases (vs prior 'not significant'); Q2 included commercial batches
Slightly overstated—revenue still immaterial; framed as 'encouraging' but unquantified
Strong order book and sequential ramp-up evident over 3–4 quarters
PI vertical and CDMO segments cite 'good visibility'; no customer names or forward quantification
Supported but opaque—no forward guidance provided
What changed on this call
New product maturity upgraded: CNS and cardiovascular now in commercial/validation phases (vs. prior 'not significant' validation batches only). Q2 included commercial quantities.
Gross margin compressed: 49% vs. ~53% prior quarter. Prior call implied stability; West Asia cost spike drives near-term pressure. Recovery dependent on Q3 pricing pass-through acceptance.
Capex and Vizag timeline reaffirmed: Mahad Unit 3 ~₹250 Cr YTD, on track H2 stream. Vizag Phase 1 ₹1,000 Cr, commercialization end FY29–FY30. No acceleration or delay.
Forward guidance deflection: Management refused to quantify Q3+ revenue or margin targets, citing CDMO business unpredictability. Unprecedented for a ₹376 Cr revenue company with stated 'good order visibility.'
How the street is positioned
The stock sits at ₹535.75, off its all-time high of ₹1,027.8 (−47.87%) and trading below its 50-day moving average of ₹542.63 but above the 200-day at ₹489.64. Price trend is neutral; RSI at 51.5 signals no directional conviction. Volume is increasing, a positive signal on institutional re-engagement.
Ownership is shifting: FII holdings fell 135 basis points year-to-date (1.97% in Q1 FY26 → 0.62% in Q2 FY27), a notable retreat. DII holdings rose 447 basis points quarter-on-quarter (4.65% → 9.12%), suggesting domestic institutions are building. Promoter stake trimmed 666 basis points QoQ (79.81% → 73.15%), a swing that reflects the ₹800 Cr qualified institutional placement (QIP) raise announced for capex funding. The QIP itself is a capital discipline signal—BJHL is funding ₹250 Cr Mahad capex and Vizag Phase 1 groundwork from equity, not debt.
The broad picture: FII retreat suggests overseas investors are uncomfortable with the guidance opacity and margin headwind; DII accumulation indicates domestic players see value in the CDMO capex thesis. The drawdown from ATH to −47.87% has reset sentiment, but the stock's trading below the 50-day average implies the post-result relief rally (if any) has already faded.
The bull-bear ledger
Exceptional 127% YoY revenue growth driven by CDMO platform ramp and first-time new product contributions.
PAT growth of 97% YoY demonstrates operational leverage even with margin compression.
Capex execution strong: Mahad Unit 3 ₹250 Cr YTD on track for H2 stream; backward integration for KSM contract media locked in.
Gross margin compressed 400 bps QoQ (49% vs. ~53%) due to West Asia raw-material inflation; recovery timing and magnitude uncertain.
Management deflected on forward guidance despite strong order book; refuses to quantify revenue or margin targets ('very hard to give sustainability').
New product contribution rising but immaterial; CNS, cardiovascular, peptide fragments still in validation/early commercial phases.
Vizag ₹1,000 Cr capex (Phase 1) won't drive material revenue until end FY29–FY30 (3+ years); execution and regulatory risk present.
FII ownership retreated 135 basis points YTD; domestic institutions building positions; promoter trimmed 666 bps QoQ for capex funding.
Ranked risks—what should concern a holder
Gross margin compression (49% from 53%, 400 bps QoQ)
HighQ3 pricing pass-throughs may not fully offset West Asia cost spike. If recovery delayed, margin stays depressed into Q4, eroding Q2–Q3 PAT growth visibility. CFO acknowledged reagent/solvent costs 'cannot pass 100%' to customers.
Forward guidance opacity
HighManagement won't quantify revenue or margin targets, claiming CDMO business makes forecasting 'impossible.' Makes quarter-to-quarter tracking opaque; valuation becomes event-driven (beat/miss cycles) rather than model-driven. Raises questions on management's own confidence.
New product revenue immateriality
MediumCNS, cardiovascular, peptide fragments, contrast media intermediate now in commercial/validation phases, but Q2 contribution negligible vs. ₹376 Cr base. If ramp-up lags, growth deceleration risk in outer years when CDMO mature phase winds down.
Vizag capex execution (₹1,000 Cr, 3+ years to commercialization)
MediumLong-dated execution window (end FY29–FY30); regulatory approvals (Environmental Clearance, land consent) required; cost/timeline slippage possible. Phase 1 includes high-intensity sweetener and peptide fragments—portfolio not yet de-risked.
Product and customer concentration
MediumContrast media flat ~$55 Mn for 3 years; KSM sweetener concentrates Vizag growth plan. Customer names not disclosed. If major customer program delays, growth outlook volatile.
FII ownership retreat
Low-MediumFII stakes down 135 bps YTD; suggests overseas investors uncomfortable with guidance opacity and margin headwind. Could signal risk re-assessment by foreign institutions; may limit upside valuation support.
The debate
1 · Q3 gross margin recovery
This is the linchpin. Management expects pricing pass-throughs to take effect in Q3. If Q3 gross margin bounces back toward 52%+ (restoring the 400 bps compression), credibility in management's 'recovery expected' messaging holds. If it stays near 49%, the bear case (structural margin pressure) gains traction.
2 · Mahad Unit 3 stream-up in H2 FY27
Backward integration for KSM contract media is the near-term capex win. On-time H2 delivery (Oct–Mar 2027) will de-risk Vizag Phase 1 and demonstrate operational discipline. Delay signals potential slippage on Vizag.
3 · New product commercialization timeline
CNS, cardiovascular, peptide fragments, and contrast media intermediate are in validation/early commercial phases. Q3–Q4 FY27 commentary on volume ramp-up (even unquantified) will indicate whether 'encouraging' is turning into material. Early revenue signals will validate the new product thesis.
4 · Forward guidance disclosure
Management's continued refusal to quantify revenue/margin targets is a red flag. If Q3 call continues to deflect, market will price in execution risk premium. Any guidance (even conservative) in Q3 would reset sentiment.
Blue Jet Healthcare delivered a headline quarter that belies underlying tension. The 127% revenue growth is real; the capex execution is solid. But gross margin compression and management silence on forward outlook signal near-term risk. The stock has reset sharply from ATH, and DII accumulation at lower prices is constructive—but overseas investors are waiting for proof. The honest read is steady execution, not a step-change. The number to track from here is Q3 gross margin: a return to 52%+ validates management's pricing-recovery thesis; a stay near 49% warns of structural margin pressure that the market has yet to price in. Capex delivery (Mahad H2 stream-up) and new product progress are secondary confirmations. Hold on fundamentals, but with conviction contingent on margin recovery and visibility.
Record growth masks margin pressure; capex on track
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 8/10
Grade A
Hit Q2 revenue target (₹375.7 Cr vs claimed ~₹376 Cr); EBITDA/PAT figures exact; Mahad capex on track (₹250 Cr reaffirmed). Prior guidance on Vizag timeline (end FY29–FY30) reaffirmed.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Blue Jet delivered 127% YoY revenue growth and 97% PAT growth on the back of CDMO scaling and new product validation. However, West Asia raw-material inflation compressed gross margin by 400 bps QoQ (49% vs 53%), and management deflected on forward guidance—won't quantify revenue or margin targets. The risk: sustaining growth while rebuilding margins from ₹1,000 Cr Vizag capex (end FY29–FY30). Strong execution track record (Mahad on time), but near-term margin recovery hinges on Q3 pricing pass-through success.
₹375.7 Cr
Revenue · +127.1% YoY₹102.5 Cr
Reported PAT · +96.6% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 revenue ~₹376 Cr with 28% QoQ growth
METDelivered ₹375.7 Cr, 28.2% QoQ growth
EBITDA 32% of operating revenue, PAT 27% of income
METEBITDA ₹119 Cr (31.7%), PAT ₹102.5 Cr (27.3%)
Gross margin 49%, down 4% QoQ; raw material inflation from West Asia
METOPM 31.6%; margin compression acknowledged, pricing pass-through pending Q3
Mahad Unit 3 ~₹250 Cr capex, on stream H2; Vizag end FY29–FY30
METPrior capex guidance matched; timeline reaffirmed
Contrast media intermediate delivered; peptide, CNS, cardiovascular in development
OVERSTATEDNew molecules now in commercial/clinical phases (vs prior 'not significant'); commercial batches already in Q2
Earnings quality
What changed since the last call
New product maturity
UpgradeCNS and cardiovascular now in commercial/validation phases vs prior 'not significant' validation batches only. Commercial batches supplied in Q2.
Mahad capex milestone
Neutral~₹250 Cr incurred YTD; on track for H2 stream. Reaffirmed prior guidance; backward integration for contract media expected.
Gross margin trajectory
DowngradeQ2 49% vs Q1 ~53% (4% compression). Prior call implied stability; West Asia cost spike drives near-term pressure. Recovery dependent on Q3 pricing.
Vizag timeline
NeutralReaffirmed end FY29–FY30 for commercialization. No acceleration; phase-1 capex ~₹1,000 Cr includes flavour compounds, sweeteners, peptide fragments.
The Q&A
Analysts pressed hard on gross margin recovery timeline, new product ramp-up quantification, PI/API order-book sustainability, and forward guidance. Management held firm on delivered numbers but deflected on forward guidance—CFO said 'very hard to give about sustainability'; COO said 'CDMO business, I don't think it is possible for anyone to give that type of guidance.' Tone: professional but defensive; no concessions on near-term margin or revenue targets.
Contrast media ramp — Amlan Das, JP Morgan
PartialNCE molecule still in clinical/commercial phases. Project intact, but volumes early-stage. Similar peptide fragment also in clinical phase; selective approach on opportunities.
ABA HCl shipment — Ravi Purohit, SIM
DodgedNot yet started shipment on iodinated ABA. Cannot confirm or deny timing. PI order book shows good sequential ramp-up over last 3–4 quarters.
Revenue growth sustainability — Shilpa Saboo, Lotus
DodgedVery hard to give about sustainability. Good order visibility and customer engagement, but no formal guidance on growth rates.
PI/API order book — Pritesh Chheda, Lucky
AnsweredGood visibility in CDMO business. Sequential ramp-up evident over last 3–4 quarters. No extrapolation recommended; strong order book.
Lateral entries and new products — Manan Vandur, Wallfert
PartialMolecules in clinical phases; not launching tomorrow. Lateral entries expected from Vizag Phase 1 when on stream. Clear long-term strategy; capacity expansion on track. Wait and watch for updates.
Gross margin recovery — Harshal Patil, ASK
AnsweredWest Asia crisis (raw material, reagents, solvents inflation across board). Cannot pass 100% of cost on reagents/solvents. Started customer negotiations; positive impact expected in coming quarters. CFO: crude price trajectory unclear; estimate conservative if crude stays high.
Contrast media sustainability — Samitinjoy Basak, Kotak
AnsweredSegment stable with multiple molecules. Good momentum; no large volume changes. Commercial products contributing alongside validation batches.
Peptide opportunity — Dheeraj Kumar Reddy, AlphaSqr
AnsweredCompany evolved on building blocks and intermediates. Peptide strategy focuses on fragments/intermediates first, then final API. Forward integration planned. Not all competitors offer this. Asset turnover historically high; specializes in fragments.
Vizag capex allocation — Ajinkya Jadhav, KRIS
PartialCDMO platform and contrast media are priorities. Sweeteners and fragments are focus. Cannot rule out GLP-1, but prioritization is unclear. Phase 1 includes multi-purpose blocks.
Contrast media pricing — Bansi Desai, JP Morgan
AnsweredNo volume degrowth in contrast media. Small volume discount present. Price pressure from customer mix variation. Growth offset by new launches and pricing dynamics. Long-term sustainable if market growth and new products scale.
PI/API commercial mix — Saket Saurabh, Sagari
AnsweredBulk is commercial; smaller value from incubated products. Asset turnover historically high. Peptide focus is fragments first. Will supply from current capacity until condensing chains on final peptide.
Vizag demand anchoring — Ravi Purohit, SIM
AnsweredHigh-intensity sweetener (Vizag portfolio addition) anchored to existing clients from current capacity. Different product from sucrose. Confident since client adjacency and low gestation period. Will not have to discover new markets.
Guidance
No numeric revenue guidance; management deflected
LowCFO: 'Very hard to give sustainability.' COO: 'CDMO business, impossible for anyone to give.' Expect Q3+ benefit from pricing pass-throughs and Mahad Unit 3 ramp, but unquantified.
Gross margin recovery from Q3 pricing; near-term pressure from raw materials
MediumWest Asia inflation acknowledged; pricing negotiations underway; some customers will have new rates from Q3. Full pass-through dependent on crude price trajectory and customer mix.
EBITDA margin 32% sustainable; no guidance on trajectory
MediumQ2 EBITDA 32% held despite gross margin compression, suggesting cost controls in place. Long-term margin profile to be anchored by Vizag economies of scale post-FY29.
Mahad Unit 3: ~₹250 Cr, on stream H2 FY27 (on track)
HighCapex incurred YTD aligns with prior guidance. Backward integration for KSM contract media; expected to drive margin uplift and margin-accretion once operational.
Vizag Units 5 & 6: ~₹1,000 Cr capex phased, commercialization end FY29–FY30
MediumPhase 1 includes contract media, sweeteners, peptide fragments, high-intensity sweetener blocks. Pre-construction activities (EC, compliance) underway. Major growth driver 3+ years out; execution risk.
Risks the call surfaced
Gross margin compression
HighWest Asia raw-material cost spike compressed Q2 gross margin to 49% from ~53% QoQ (4% hit). Pricing pass-throughs pending Q3; if delayed or partial, margin stays depressed into Q4.
New product revenue immateriality
MediumCNS, cardiovascular, peptide fragments, contrast media intermediate now in commercial/validation phases. Q2 contribution 'not significant' (per prior call framing). If ramp-up lags expectations, growth deceleration risk in outer years.
Vizag capex execution
Medium₹1,000 Cr capex over multiple phases; commercialization end FY29–FY30 (3+ years). Regulatory approvals (EC), land consent in place. Pre-construction phase underway. Execution window is long; cost/timeline slippage possible.
Forward guidance opacity
MediumManagement refused to give numeric revenue or margin guidance for coming quarters. Says 'very hard to give sustainability' and CDMO business 'impossible for anyone to give that type of guidance.' Makes near-term tracking difficult.
Product concentration and customer concentration
LowContrast media stable but base flat $55 Mn for 3 years; KSM sweetener concentration in Vizag growth plan. Customer names not disclosed. If major customer program delays or shifts, growth outlook becomes volatile.
Management
Score 7/10. Clear on numbers and capex milestones; evasive on forward guidance. CFO and COO cite CDMO business unpredictability to deflect on revenue/margin targets. Transparent on cost pressures (West Asia, raw material) but non-committal on recovery timing. Strong track record on capex (Mahad on time, Vizag on schedule). Hit Q2 numbers (₹375.7 Cr vs claimed ~₹376 Cr). Prior guidance reaffirmed (₹250 Cr capex, Vizag end FY29–FY30). New product development advancing but revenue still immaterial.
1 · Q3 FY27 (Sep 2026)
Gross margin recovery from raw-material pricing pass-throughs
2 · H2 FY27 (Oct–Mar 2027)
Mahad Unit 3 on stream; initial KSM contract media backward integration
3 · FY29–FY30
Vizag Units 5 & 6 commercialization; large-scale CDMO capacity online
Strong execution track record (Mahad on time), but near-term margin recovery hinges on Q3 pricing pass-through success.